US2013084300A1PendingUtilityA1

Diagnosis and prevention of cancer cell invasion

38
Assignee: ULLRICH AXELPriority: Jul 17, 2002Filed: Aug 31, 2012Published: Apr 4, 2013
Est. expiryJul 17, 2022(expired)· nominal 20-yr term from priority
Inventors:Axel UllrichPjotr KnyazevTatjana KnyazevaYuri Cheburkin
A61P 43/00A61P 35/00C12Q 1/6886A61K 39/3955A61K 2039/505C12Q 2600/136A61P 35/04C07K 16/2863
38
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to diagnostic and therapeutic methods in the field of malignant disorders. More particularly, the invention provides methods of determining the invasivity of malignant disorders and methods for reducing the invasivity of malignant disorders including the prevention or treatment of cancer cell invasion.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising as an active agent an inhibitor of the AXL gene, AXL ligand gene, AXL protein and/or AXL protein ligand together with pharmacologically active diluents, carriers and/or adjuvants. 
     
     
         2 . The composition of  claim 1 , wherein the inhibitor is an antibody directed against the AXL protein. 
     
     
         3 . The composition of  claim 1 , wherein the inhibitor is an antisense nucleic acid, a ribozyme or an RNA interference molecule directed against the AXL gene or a transcript thereof. 
     
     
         4 . The composition of  claim 1 , wherein the inhibitor is a dominant-negative mutant of the AXL gene. 
     
     
         5 . The composition of  claim 1 , wherein the inhibitor is a low molecular weight compound. 
     
     
         6 . The composition of  claim 1  for reducing the invasivity of a malignant disorder. 
     
     
         7 . The composition of  claim 1  for reducing the metastasis formation in a malignant disorder. 
     
     
         8 . The composition of  claim 6 , wherein the malignant disorder is glioblastoma. 
     
     
         9 . The composition of  claim 1  comprising at least one further active agent. 
     
     
         10 . The composition of  claim 9 , wherein the further active agent is a cytotoxic or cytostatic agent. 
     
     
         11 . An inhibitor of the AXL gene, AXL ligand gene, AXL protein and/or AXL protein ligand. 
     
     
         12 . The inhibitor of  claim 11  which is an antibody directed against the AXL protein. 
     
     
         13 . The inhibitor of  claim 11  which is an antisense nucleic acid, a ribozyme or an RNA interference molecule directed against the AXL gene or a transcript thereof. 
     
     
         14 . The inhibitor of  claim 11  which is a dominant-negative mutant of the AXL gene. 
     
     
         15 . The inhibitor of  claim 11 , wherein the inhibitor is a low molecular weight compound. 
     
     
         16 . The inhibitor of  claim 11  for reducing the invasivity of a malignant disorder. 
     
     
         17 . The inhibitor of  claim 11  for reducing the metastasis formation in a malignant disorder. 
     
     
         18 . The inhibitor of  claim 16 , wherein the malignant disorder is glioblastoma. 
     
     
         19 . The composition of  claim 7 , wherein the malignant disorder is glioblastoma. 
     
     
         20 . The inhibitor of  claim 17 , wherein the malignant disorder is glioblastoma.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.